ODE (office of device evaluation) deputy steps up to top role
This article was originally published in Clinica
Daniel Schultz, deputy director for clinical and review policy at the US FDA's office of device evaluation (ODE), has moved up to become office director. He replaces Bernard Statland, who left this week to return to law school. "Dan brings to the job a wealth of clinical and administrative experience that should prove invaluable in overseeing the evaluation of new medical devices," David Feigal, director of the Center for Devices and Radiological Health said in announcing the appointment.